A Phase 3 interventional study of Mesh repair and Conventional facial closure in Incisional Hernia and Pelvic Cancer, sponsored by University of Aarhus. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-09-09.
Sponsored by University of Aarhus · Phase 3, Interventional, and Prevention
The aim of the present project is to investigate whether use of biological mesh at the donor site of the rotation flap in closure of the abdominal wall reduce the frequency of incisional hernia formation compared to the usual abdominal wall closure after abdominal rotation flap operation in surgery for advanced pelvic cancer.
98 studies on the registry are indexed under Pelvic Neoplasms; 27 are open to participants now.
This study's enrollment of 59 is above the median of 42 across 63 interventional studies indexed under Pelvic Neoplasms.
Browse Pelvic Neoplasms studies →University of Aarhus is the lead sponsor of 1,274 studies on the registry; 183 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
No previous major abdominal surgery
Procedure: Mesh repair · Procedure: Conventional facial closure
Previous major abdominal surgery
Procedure: Mesh repair · Procedure: Conventional facial closure
A Surgisis Gold Hernia repair graft (Cook Biotech Incorporated, West Lafayette, IN, U.S.A) is placed at the donor site of the rectus abdominis muscles used for the rotation flap before the abdominal fascia is sutured with continuous running suture.
Also known as: Surgisis Gold Hernia repair graft
The abdominal facia is closed with with continuous running suture
incisional hernia formation determined by CT scan 1 year postoperative
Time frame: 1 year postoperative
postoperative morbidity
Time frame: 30 days postoperative
This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Aarhus